Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
Glucocorticoids have been the primary treatment of graft-versus-host disease (GVHD) over the past decade. Complete responses to steroid therapy are usually expected in almost one-third of aGVHD cases and partial response is anticipated in another one-third of patients. However, for those patients no...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2014/980301 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561685183856640 |
|---|---|
| author | Amr Nassar Ghada Elgohary Tusneem Elhassan Zubeir Nurgat Said Y. Mohamed Mahmoud Aljurf |
| author_facet | Amr Nassar Ghada Elgohary Tusneem Elhassan Zubeir Nurgat Said Y. Mohamed Mahmoud Aljurf |
| author_sort | Amr Nassar |
| collection | DOAJ |
| description | Glucocorticoids have been the primary treatment of graft-versus-host disease (GVHD) over the past decade. Complete responses to steroid therapy are usually expected in almost one-third of aGVHD cases and partial response is anticipated in another one-third of patients. However, for those patients not responding to corticosteroid treatment, there is no standard second-line therapy for acute or chronic GVHD. Methotrexate (MTX) for treatment of steroid refractory GVHD has been evaluated in a number of studies. Results from peer-reviewed original articles were identified and the pooled data analyzed. Despite several limitations in data collection and analysis, weekly administration of methotrexate at a median dose of 7.5 mg/m2 seems to be safe with minimal toxicities in the context of both aGVHD and cGVHD treatments. The observed overall response (OR) in patients with aGVHD to MTX treatment in the published studies was 69.9%, with complete response (CR) in 59.2% and PR in 10.6%. In cGVHD the OR was 77.6%, with CR reported in 49.6% and PR in 28% of patients. Predictors of better responses were lower grade GVHD, cutaneous involvement, and isolated organ involvement. MTX as a steroid sparing agent might reduce long-term complications and improve the quality of life of GVHD affected individuals. |
| format | Article |
| id | doaj-art-0bf4228482f24d1997c5ac8bf0d51d39 |
| institution | Kabale University |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-0bf4228482f24d1997c5ac8bf0d51d392025-02-03T01:24:25ZengWileyJournal of Transplantation2090-00072090-00152014-01-01201410.1155/2014/980301980301Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell TransplantationAmr Nassar0Ghada Elgohary1Tusneem Elhassan2Zubeir Nurgat3Said Y. Mohamed4Mahmoud Aljurf5National Research Center, Tahrir Street, Cairo, EgyptAdult HSCT Program, Ain Shams University Hospitals, P.O. Box 1156, Cairo, EgyptAdult HSCT Program, Oncology Center, King Faisal Specialist Hospital & Research Center, P.O. Box 3354, Riyadh 11211, Saudi ArabiaPharmaceutical Care Division, King Faisal Specialist Hospital & Research Center, P.O. BOX 3354, Riyadh 11211, Saudi ArabiaAdult HSCT Program, Ain Shams University Hospitals, P.O. Box 1156, Cairo, EgyptAdult HSCT Program, Oncology Center, King Faisal Specialist Hospital & Research Center, P.O. Box 3354, Riyadh 11211, Saudi ArabiaGlucocorticoids have been the primary treatment of graft-versus-host disease (GVHD) over the past decade. Complete responses to steroid therapy are usually expected in almost one-third of aGVHD cases and partial response is anticipated in another one-third of patients. However, for those patients not responding to corticosteroid treatment, there is no standard second-line therapy for acute or chronic GVHD. Methotrexate (MTX) for treatment of steroid refractory GVHD has been evaluated in a number of studies. Results from peer-reviewed original articles were identified and the pooled data analyzed. Despite several limitations in data collection and analysis, weekly administration of methotrexate at a median dose of 7.5 mg/m2 seems to be safe with minimal toxicities in the context of both aGVHD and cGVHD treatments. The observed overall response (OR) in patients with aGVHD to MTX treatment in the published studies was 69.9%, with complete response (CR) in 59.2% and PR in 10.6%. In cGVHD the OR was 77.6%, with CR reported in 49.6% and PR in 28% of patients. Predictors of better responses were lower grade GVHD, cutaneous involvement, and isolated organ involvement. MTX as a steroid sparing agent might reduce long-term complications and improve the quality of life of GVHD affected individuals.http://dx.doi.org/10.1155/2014/980301 |
| spellingShingle | Amr Nassar Ghada Elgohary Tusneem Elhassan Zubeir Nurgat Said Y. Mohamed Mahmoud Aljurf Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Journal of Transplantation |
| title | Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| title_full | Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| title_fullStr | Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| title_full_unstemmed | Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| title_short | Methotrexate for the Treatment of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation |
| title_sort | methotrexate for the treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation |
| url | http://dx.doi.org/10.1155/2014/980301 |
| work_keys_str_mv | AT amrnassar methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation AT ghadaelgohary methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation AT tusneemelhassan methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation AT zubeirnurgat methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation AT saidymohamed methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation AT mahmoudaljurf methotrexateforthetreatmentofgraftversushostdiseaseafterallogeneichematopoieticstemcelltransplantation |